CODEXIS INC (CDXS)
US1920051067 - Common Stock
Codexis to Report First Quarter 2024 Financial Results on May 2
REDWOOD CITY, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will...
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
Cobb adds RNA industry operations and commercial expertise to support continued development of ECO Synthesis™ manufacturing platform...
Commit To Buy Codexis At $2.50, Earn 20.1% Annualized Using Options
Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Anticipate 2024 Product Revenue Growth of at Least 10% vs. 2023 Excluding Enzyme Sales Related to PAXLOVID™ Recently Announced Debt Financing Reinforces...
Codexis stock climbs 11% on Roche licensing deal for DNA ligases (NASDAQ:CDXS)
Codexis (CDXS) stock climbed 11% in post-market trading after the company said it had granted an exclusive global license to Roche (RHHBY) for its EvoT4 DNA and new dsDNA ligases.
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has...
Codexis to Participate in TD Cowen 44th Annual Health Care Conference
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company...
Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board
Board expertise encompasses oligonucleotide research, development, manufacturing and commercialization to support development of ECO Synthesis™...
Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28
REDWOOD CITY, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will...
Codexis gets $40M financing deal with Innovatus Capital Partners (NASDAQ:CDXS)
Codexis secures $40 million loan facility from Innovatus Capital Partners, with $30 million upfront and potential for an additional $10 million.
Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones
Term loan agreement enables Company to accelerate development and enhance commercialization of ECO Synthesis™ manufacturing platform for RNAi therapeutics ...
seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting
TnX transposase development collaboration leverages strengths of both companies...
Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108
Company to retain economic interest in biotherapeutic asset while removing cash burn from development and commercialization costs...
Commit To Buy Codexis At $2.50, Earn 19.7% Annualized Using Options
Biggest stock movers today: Adobe, Ocular Therapeutix and more (NASDAQ:CDXS)
Stock futures slightly rose in the premarket hours on Thursday following the Federal Reserve's indication of potential 75 basis points of rate cuts in 2024. Her
Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase
Deal creates strategic collaboration to enable more efficient RNA therapeutic development, providing a path to GMP-grade Codexis enzymes...
Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis™ Platform
Milestone enables Codexis engineers to model the manufacturing process for RNAi therapeutics Company remains on track to initiate pre-commercial customer...
Codexis KOL Event Highlights Significant Need for an Enzymatic Route of Synthesis in RNAi Therapeutics Manufacturing
REDWOOD CITY, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, hosted a virtual Key Opinion...
KeyBanc sees opportunity in tech-enabled drug discovery stocks (NASDAQ:ABCL)
KeyBanc has initiated coverage of the tech-enabled drug discovery subsector, citing increasing demand for products that can help lower drug development costs. Read more here.
3 Synthetic Biology Stocks Likely to Mint New Millionaires
Synthetic biology stocks are strongly worth considering for several reasons, particularly these three stocks.
Codexis to Host Virtual KOL Event on its ECO Synthesis™ Platform and the Future of RNAi Therapeutics Manufacturing on December 8, 2023
REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it will host...
Codexis to Participate in 35th Annual Piper Sandler Healthcare Conference
REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company...
Codexis Reports Third Quarter 2023 Financial Results
Company Remains on Track to Demonstrate Gram-Scale Synthesis with ECO Synthesis™ Platform for RNAi Therapeutics Production by End of Year Strong Financial...
Codexis to Participate in Upcoming Healthcare Conferences
REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that...
Codexis to Present Update on ECO Synthesis™ Platform at TIDES Europe
REDWOOD CITY, Calif., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced a...
Codexis to Present Update on ECO Synthesis™ Platform at TIDES Europe
REDWOOD CITY, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced a...
Codexis to Report Third Quarter 2023 Financial Results on November 2
REDWOOD CITY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will...